Italia - italiensk - Ministero della Salute

orqis medical corporation -

Kroatia - kroatisk - HALMED (Agencija za lijekove i medicinske proizvode)

alpha-medical d.o.o., dragutina golika 36, zagreb, hrvatska - эфавиренз - filmom obložena tableta - 600 mg - urbroj: jedna filmom obložena tableta sadrži 600 mg efavirenza

USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - isotretinoin (unii: eh28up18if) (isotretinoin - unii:eh28up18if) - isotretinoin 40 mg - myorisan is indicated for the treatment of severe recalcitrant nodular acne. nodules are inflammatory lesions with a diameter of 5 mm or greater. the nodules may become suppurative or hemorrhagic. “severe,” by definition,2 means “many” as opposed to “few or several” nodules. because of significant adverse effects associated with its use, myorisan  should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. in addition, myorisan is indicated only for those female patients who are not pregnant, because myorisan can cause severe birth defects (see boxed contraindications and warnings ). a single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients.1,3,4 if a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off myorisa

USA - engelsk - NLM (National Library of Medicine)

akorn operating company llc - isotretinoin (unii: eh28up18if) (isotretinoin - unii:eh28up18if) - isotretinoin 10 mg - myorisan® is indicated for the treatment of severe recalcitrant nodular acne. nodules are inflammatory lesions with a diameter of 5 mm or greater. the nodules may become suppurative or hemorrhagic. “severe,” by definition,2 means “many” as opposed to “few or several” nodules. because of significant adverse effects associated with its use, myorisan ®  should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. in addition, myorisan® is indicated only for those patients who are not pregnant, because myorisan® can cause life-threatening birth defects (see boxed contraindications and warnings ). a single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients.1,3,4 if a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve whi

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b-medical b.v. - chlorhydrate de labétalol 5 mg/ml - solution injectable - 5 mg/ml - chlorhydrate de labétalol 5 mg/ml - labetalol

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b-medical b.v. - pémétrexed disodique 604 mg - eq. pémétrexed 500 mg - poudre pour solution à diluer pour perfusion - 500 mg - pémétrexed disodique 604 mg - pemetrexed

Belgia - fransk - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

medical developments ned b.v. - méthoxyflurane 99,9 % w/w - liquide pour inhalation par vapeur - 99,9 % - méthoxyflurane - methoxyflurane

Den europeiske union - portugisisk - EMA (European Medicines Agency)

pfizer europe ma eeig - temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - agentes antineoplásicos - renal-célula carcinomatorisel é indicado para o tratamento de primeira linha de pacientes adultos com avançada renal-carcinoma de células (rcc), que têm, pelo menos, três dos seis prognóstica fatores de risco. manto-célula lymphomatorisel é indicado para o tratamento de pacientes adultos com recidiva e / ou refratários manto linfoma de células (mcl).

Den europeiske union - fransk - EMA (European Medicines Agency)

pfizer europe ma eeig - le temsirolimus - carcinoma, renal cell; lymphoma, mantle-cell - agents antinéoplasiques - rénal à cellules carcinomatorisel est indiqué pour le traitement de première ligne chez les patients adultes atteints rénal avancé de cellules de carcinome (rcc) qui ont au moins trois des six pronostique des facteurs de risque. À cellules du manteau lymphomatorisel est indiqué pour le traitement des patients adultes en rechute et / ou réfractaire lymphome à cellules du manteau (mcl).

Romania - rumensk - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - combinatii (losartanum+hydrochlorothiazidum) - compr. film. - 100mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic